The third through sixth participant may enroll no sooner than 48 hours after the most recent enrollee. Once six participants have enrolled and been found to be safe further participants may enroll at any time . • Although positive HPV testing will not be required prior to enrolling, HPV testing will be offered as an exploratory endpoint and participants testing negative for HPV after enrolling or whose HPV status cannot be confirmed may be replaced with other participants for the primary efficacy analysis. Participants testing negative for HPV after enrolling or whose HPV status cannot be confirmed may continue to receive treatment on study. • The combination of PDS0101+ NHS -IL12+ M7824 will be evaluated in all HPV serotypes given the clinical remissions PDS Biotechnology has observed in CIN studies with PDS0101 in non- HPV 16 serotypes. However, if it is found that the ORR with non- HPV- 36 Abbreviated Title: Combo Immunotx in HPV Cancers Version Date: 05.12.2023 16 serotypes is noticeably less than the ORR observed with HPV 16 serotypes than participants having disease related to non- HPV- 16 serotypes may be replaced with participants having disease related to the HPV -16 serotype for the first and second stage of the primary efficacy analyses. • In addition, while the primary focus of this protocol is to evaluate the response rate of this I/O combination in participants with a wide array of HPV associated malignancies, if the I/O combination in not deemed to be promising in this larger population (less than three out of eight evaluable participants have a response) than the study will be amended to evaluate this I/O combination specifically in participants with cervical cancer (and participants who have already been enrolled with non -cervical cancers may be replaced with cervical cancer participants for the first stage of the primary efficacy analyses) . • While checkpoint refractory participants will be eligible to enroll, the primary objective of response rate will be determined among the checkpoint naïve participants and the response rate among checkpoint refractory participants will be an exploratory objective. 37 Abbreviated Title: Combo Immunotx in HPV Cancers Version Date: 05.12.2023 Figure 19.